Aligos Therapeutics, Inc (NASDAQ:ALGS) has spent 2026 stacking up clinical and commercial milestones even as its shares remain squarely in small-cap territory. The Nasdaq-listed, clinical-stage biopharmaceutical is best known for its hepatitis B program, and this year it added a marquee licensing deal and …
● A quiet uptick has kept Amarin on investors' radar as the cardiovascular-drug maker works to prove there is life beyond its once-blockbuster U.S.
The most important fact about Anebulo Pharmaceuticals, Inc. (OTC:ANEB) is not any single day's price change but where the stock now lives. In early 2026 the clinical-stage biotech chose to leave theNasdaqand step back from full SEC reporting, a decision that fundamentally changes how …
When a stock already trades for a fraction of a cent, a steep percentage drop can look alarming while signifying very little in absolute terms. That is the situation facing Aoxing Pharmaceutical Company, Inc (OTC:AOXG), a China-focused specialty-pharmaceutical name whose shares now change hands …
Few micro-cap healthcare names have reinvented themselves as abruptly as Apimeds Pharmaceuticals US, Inc (NYSE American:APUS). A specialty pharmaceutical company that only completed its initial public offering in May 2025, Apimeds has since bolted a cryptocurrency-treasury strategy onto its business, merging with MindWave Innovations …
Acutus Medical Inc (OTC:AFIB) is a cautionary tale of a once-Nasdaq-listed medical-device maker that has effectively wound down its commercial ambitions. Formerly a developer of catheter-based tools for treating cardiac arrhythmias, the company has retreated to a narrow manufacturing-and-distribution role and now trades on …
A single-day surge of the kind flagged for Aibotics Inc (OTC:AIBT) is exactly the sort of move that turns speculative eyes toward a sub-penny stock, and exactly the sort that deserves scrutiny before any excitement. Aibotics trades for a tiny fraction of a cent …
Firefly Neuroscience has spent 2026 building a case that artificial intelligence can sharpen how clinicians read the brain, yet its shares remain caught in theVolatilitycommon to micro-capMedTechnames. On September 9, 2026, the stock closed near $1.06, giving the Nasdaq-listed company a market value of …
Few small-cap biotechs have tested investor patience quite like ADC Therapeutics (NYSE: ADCT). The commercial-stage cancer-drug maker, best known for its approved lymphoma therapy ZYNLONTA, has seen its shares slide to around $1.22, leaving a marketCapitalizationnear $156 million. The latest roughly 6% retreat keeps …
Adagio Medical Holdings (NASDAQ:ADGM) sits at an unusual crossroads: a medical-device company advancing a differentiated cardiac-ablation platform through late-stage regulatory milestones, yet trading as a deeply depressed micro-cap near 60 cents. That tension, clinical and regulatory momentum on one side and a fragileMarket Valueand …